Jeffrey Balzer, PhDAssociate Professor of Neurological Surgery, Neuroscience & Acute and Tertiary Care Nursing
Director, Clinical Services, Center for Clinical Neurophysiology
Director, Cerebral Blood Flow Laboratory
Jeffrey Balzer, PhD, is director of clinical operations and staff clinical neurophysiologist at the Center for Clinical Neurophysiology and director of the Cerebral Blood Flow Laboratory at the University of Pittsburgh Medical Center.
His current research interests range from the utilization of genetic biomarkers for the prediction of delayed cerebral ischemia in subarachnoid hemorrhage to the use of blood flow measures in mild head injury and concussion to vagal nerve stimulation to control cardiac arythmias. Dr. Balzer received his undergraduate education at the University of Pittsburgh, where he also pursued a graduate education and a PhD in behavioral neuroscience.
Dr. Balzer is also the secretary/treasurer of the American Board of Neurophysiological Monitoring and on the board of directors of the American
Society of Neurophysiological Monitoring He has published 56 refereed articles and 12 book chapters.
Dr. Balzer's publications can be reviewed through the National Library of Medicine's publication database.
Specialized Areas of Interest
Intraoperative neurophysiological monitoring, subarachnoid hemorrhage, concussion, cerebral blood flow.
American Board of Neurophysiological Monitoring
Children’s Hospital of Pittsburgh of UPMC
Monongahela Valley Hospital
UPMC St. Margaret’s
Professional Organization Membership
American Clinical Neurophysiology Society
American Association for the Advancement of Science
American Society for Neurophysiological Monitoring (Fellow)
New York Academy of Sciences
Pittsburgh Neuroscience Society
Dr. Balzer has continued to work with the SAH investigational group exploring the relationship between SAH, genetic biomarkers and neurological outcomes. Their work in the past year has culminated in several significant publications. Specifically, they have demonstrated that CSF 20-HETE is independently associated with an over three-fold increase in mortality in the SAH patient population; thereby implicating 20-HETE as one of the only known markers associated with mortality in SAH patient. It is notable that this group was the first to report the association of 20-HETE with patient outcomes. These results were recently published in the Journal of Cerebral Blood Flow and Metabolism.
In addition to research in SAH, Dr. Balzer was involved in a multicenter trial investigating methods to improve the safety of XLIF spine procedures with Adam Kanter, MD. They, and others, recently published these results in the European Spine Journal. Dr. Balzer is now engaged in an additional multi-center trial testing innovative IOM strategies during these same procedures.
Other research included the use of evoked potentials to predict delayed cerebral ischemia in the high-grade SAH patient population, being conducted as part of a Copeland award, and an outcome study investigating the implications of balloon remodeling during endovascular treatment of aneurysms, with Andrew Ducruet, MD.